HomeNYSE:NVS

NYSE:NVS

Novartis Reports Positive Results for Kidney Disease Drug

Novartis Reports Positive Results for Kidney Disease Drug

October 3, 2023

Novartis Reports Positive Phase III Results for Lutathera in GEP-NETs

Novartis Reports Positive Phase III Results for Lutathera in GEP-NETs

September 25, 2023

Novartis Stock Surged as Company Announces a $15 Billion Stock Repurchase Program

Novartis Stock Surged as Company Announces a $15 Billion Stock Repurchase Program

July 18, 2023

NVS Stock Rises as Nilotinib, a Leukemia Medication Is Licensed by Novartis to the Un-Backed Medicines Patent Pool

NVS Stock Rises as Nilotinib, a Leukemia Medication Is Licensed by Novartis to the Un-Backed Medicines Patent Pool

October 20, 2022

Novartis’ Drug for Chronic Myeloid Leukemia Receives EC Approval

Novartis’ Drug for Chronic Myeloid Leukemia Receives EC Approval

August 30, 2022